Research tools
Biomarker articles covering signals used to study, predict, monitor, or measure Crohn's disease and IBD activity or treatment response.
Page 2 of 6 · 241 articles
Circulating glycoprotein signals may help explain how systemic inflammation in IBD interacts with metabolic liver disease (MASLD). If validated, they could improve risk stratification for liver complications beyond...
IBD and obstructive sleep apnea may influence each other through shared biological processes (barrier dysfunction, dysbiosis, immune activation, intermittent hypoxia), so understanding this could affect screening and...
ER stress may be a pathway connecting what people eat with intestinal inflammation in IBD. Understanding this could eventually help tailor diets or develop therapies, but human evidence is still limited.
If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...
This study describes an engineered probiotic that senses a validated IBD inflammation biomarker (calprotectin) and produces IL‑2 locally, offering a potential new way to deliver anti‑inflammatory therapy on demand.
Cure8 could only read part of this source from INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, so this card uses cautious topic tags instead of a full summary. It is tagged...
AI tools for endoscopic and multimodal IBD assessment could make scoring and monitoring more objective and consistent, which matters for treatment decisions and tracking remission or relapse. The review also flags...
Microbial amino-acid metabolites may be active players in IBD biology and could become useful biomarkers or therapeutic targets. Understanding these metabolites helps explain links between the microbiome, immune...
A blood biomarker that flags higher risk for complicated Crohn's could help identify people who may need closer monitoring or earlier treatment escalation before clear symptoms or endoscopic inflammation appear.
Identifies IL-1RN and SERPINA1 as biomarkers linked to macrophage-driven inflammation in ulcerative colitis and shows TolDCs can reduce macrophage pro-inflammatory cytokine expression in lab experiments — findings that...
The study tests whether common environmental chemicals (PFAS) could alter protein glycosylation and raise the later risk of IBD, which could point to preventable risk factors and early biomarkers.
miRNAs are being studied as stable circulating biomarkers and possible therapeutic targets in immune diseases including IBD. Advances could eventually improve earlier diagnosis, track disease course, or lead to new...
The pipeline helps identify stem and progenitor epithelial cell states linked to inflammation in IBD. Knowing these cell states and biomarkers could guide research into disease mechanisms, tissue repair, and potential...
The exposome perspective emphasizes that many non-genetic, potentially modifiable environmental factors likely influence IBD risk. Understanding these factors could help guide prevention research and public-health...
A blood biomarker that helps predict primary non-response to anti‑TNF drugs could spare some patients ineffective therapy, reduce delays to alternative treatments, and inform shared decision‑making before starting...
The study links high levels of the bile acid DCA to microbiome and metabolite changes that correlate with intestinal inflammation in mice, suggesting a possible pathway connecting high‑fat diets to colitis risk.
PSC commonly co-occurs with IBD in children; understanding clinical phenotypes and reliable monitoring tools helps families and clinicians track disease and plan follow-up.
Spatially resolved profiling could identify the specific cell neighborhoods and signaling circuits that drive disease in a person’s gut tissue, which may help predict who will respond to particular biologics or small...
A blood biomarker that tracks both symptoms and endoscopic inflammation could help with noninvasive monitoring of ulcerative colitis activity and reduce reliance on invasive procedures if validated.
Postoperative recurrence is common after intestinal resection for Crohn's disease, but clinicians currently lack reliable molecular biomarkers or validated models to predict who will relapse.
Biopsy-based keratin patterns might help distinguish IBD, microscopic colitis, and IBS—conditions that can look similar clinically—so this could improve diagnostic accuracy if validated.
Many people with UC try dietary supplements; this randomized trial tested grape seed extract and found a measurable reduction in an inflammation blood marker (hs‑CRP) but no clear improvement in most other measured...
The paper suggests that the same herbal formula can produce different absorbed components and target interactions depending on oral versus colonic delivery, which could influence therapeutic effects in ulcerative colitis...
A simple blood-derived neutrophil activation marker (Neut-RI) correlated with clinical disease activity in ulcerative colitis and outperformed fecal calprotectin and CRP in this study, suggesting a potential low-cost,...
If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people...
The study shows that fecal (luminal) and mucosal microbiome and metabolite profiles capture different aspects of pediatric IBD—activity versus phenotype—so combined sampling may give a fuller picture for research and...
A blood biomarker that reliably indicates mucosal healing could reduce reliance on colonoscopy, help monitor disease activity more frequently, and better guide treatment decisions in UC.
Serum LRG1 is a candidate blood biomarker for mucosal inflammation in UC, but anti-TNF drugs may suppress its levels and cause false-negative results. This affects noninvasive monitoring and decisions based on LRG1...
If validated, serum osmolality — a routine, low-cost blood measure — could become an additional marker to help identify IBD in certain hospitalized patients with anxiety. This could aid research and possibly improve...
Patients with ulcerative colitis may develop advanced neoplasia after seemingly complete endoscopic removal of dysplasia. Detecting genomic alterations in adjacent, histologically normal margins could identify...
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of...
The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemia medica.
Identifies a stromal-cell subset marked by TIMP1 that may play a role in UC pathogenesis and might serve as a candidate biomarker or therapeutic target; useful for researchers and clinicians following emerging...
This review highlights shared biomarkers and mechanisms between early Crohn's disease and post-operative recurrence, which could improve prediction and lead to preventive strategies for recurrence after surgery.
This study links genetic variation in fatty-acid–desaturase genes with membrane PUFA profiles and inflammatory markers in Crohn’s disease. If replicated, erythrocyte desaturase indices could become integrative biomarkers...
Researchers found that nearly all people with UC have high-titer autoantibodies to the epithelial integrin αvβ6 that can precede disease and associate with worse outcomes. Understanding whether and how these antibodies...
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...
Oral and upper-GI involvement in Crohn's can be missed and may change how disease is diagnosed and managed. A focused review helps clinicians and researchers spot gaps in diagnostics and treatment research.
This study reports a non-invasive fluorescence probe that detects a reactive nitrogen species (peroxynitrite) linked to intestinal inflammation and shows signal changes in cells, animal models, and mouse feces — a...
If blood bile acid patterns are reproducibly different in IBD and track with disease activity, they could become noninvasive biomarkers to help diagnose IBD or monitor flares. That would be useful for patients and...
Non-invasive, portable tests that can track inflammation more frequently could help patients and clinicians monitor disease activity between clinic visits and guide treatment decisions without repeated invasive...
People with IBD are at higher risk for colorectal cancer; identifying stromal genes that track inflammation-driven EMT could help researchers find biomarkers or targets that explain how chronic inflammation promotes...
A blood test (serum REG3α) may help identify people at higher risk of developing complicated Crohn's disease years before diagnosis and predict progression in established disease, which could inform monitoring or early...
Finding reliable blood biomarkers for ulcerative colitis activity could make monitoring disease flares easier and less dependent on invasive tests. NGAL and S100A12 rising with active disease suggests they might help...
